ArticleNature immunology2025
Short IL-18 generated by caspase-3 cleavage mobilizes NK cells to suppress tumor growth.
Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Caspase-1 boosts immunotherapeutic efficacy via induction of CD8Science China. Life sciences · 2026Article
- Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy.Nature cancer · 2026Article
- IL-18 suppresses retinoblastoma growth while concomitantly inducing an inflammation-/stress-associated and immune-remodeling response.Cancer cell international · 2026Article
- Review
- NIR-II imaging-guided nanoplatform for synergistic mitochondria-targeted pyroptosis and macrophage reprogramming immunotherapy.Materials today. Bio · 2026Article
- The Roles of Interleukin-18 in Inflammation and Autoimmune Disease.Clinical reviews in allergy & immunology · 2026Review
- IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026Review
- Exercise-secreted antitumor myokines: mechanistic insights and translational potential.Frontiers in sports and active living · 2026Review
- Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor".Oncology research · 2026Review
- Aging modulation of the immune system and immunotherapy efficacy in cancer.Frontiers in immunology · 2026Review
- Multidimensional plasticity of natural killer cells in tumours.Cell death & disease · 2025Review
- A Novel Zinc(II) Complex for Sonodynamic Therapy Induces Pyroptosis of Breast Cancer Cells and Enhances Anti-Tumor Immune Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Genetic insights into acute lymphoblastic leukemia: the role of MDR1 and IL18 polymorphisms in Egyptian children.BMC cancer · 2025Article
- IL-1 family cytokines in inflammation and immunity.Cellular & molecular immunology · 2025Review
- Prognostic significance of key immune cell functional alterations in clear cell renal cell carcinoma.Translational cancer research · 2025Article
- Machine learning identifies lactate metabolism biomarkers and deciphers immune infiltration landscapes in Parkinson's disease.Scientific reports · 2025Article
- Specific signaling pathways mediated programmed cell death in tumor microenvironment and target therapies.Discover oncology · 2025Review
- Tumor immunology: a short IL18 cleavage product promotes cancer immunosurveillance.Signal transduction and targeted therapy · 2025Article
- The dual-function of HSP70 in immune response and tumor immunity: from molecular regulation to therapeutic innovations.Frontiers in immunology · 2025Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
Abstract
Interleukin (IL)-18 functions primarily through its 18-kDa mature form produced from caspase-1 cleavage. However, IL-18 can also be processed by other proteases, leading to the generation of different fragments with less recognized functions. Here, we discover that, in cancer cells, caspase-3 cleavage of IL-18 generates a 15-kDa form of IL-18, referred to as short IL-18. Unlike mature IL-18, short IL-18 is not secreted, and does not bind IL-18Rα; instead, it translocates into the nucleus, facilitating STAT1 phosphorylation at Ser
Indexed as
Identifiers
39891018What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.